Oncopeptides (Sweden) Performance
| ONCO Stock | SEK 1.51 0.01 0.67% |
The company holds a Beta of 0.36, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oncopeptides' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncopeptides is expected to be smaller as well. At this point, Oncopeptides AB has a negative expected return of -0.49%. Please make sure to check Oncopeptides' coefficient of variation, information ratio, total risk alpha, as well as the relationship between the standard deviation and jensen alpha , to decide if Oncopeptides AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 840.3 M | |
| Total Cashflows From Investing Activities | -339 K |
Oncopeptides |
Oncopeptides Relative Risk vs. Return Landscape
If you would invest 217.00 in Oncopeptides AB on August 29, 2024 and sell it today you would lose (66.00) from holding Oncopeptides AB or give up 30.41% of portfolio value over 90 days. Oncopeptides AB is generating negative expected returns and assumes 3.8258% volatility on return distribution over the 90 days horizon. Simply put, 34% of stocks are less volatile than Oncopeptides, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oncopeptides Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncopeptides' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncopeptides AB, and traders can use it to determine the average amount a Oncopeptides' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1271
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONCO |
Estimated Market Risk
| 3.83 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oncopeptides is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncopeptides by adding Oncopeptides to a well-diversified portfolio.
Oncopeptides Fundamentals Growth
Oncopeptides Stock prices reflect investors' perceptions of the future prospects and financial health of Oncopeptides, and Oncopeptides fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncopeptides Stock performance.
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Operating Margin | 49.84 % | |||
| Current Valuation | 776.19 M | |||
| Shares Outstanding | 90.37 M | |||
| Price To Book | 2.96 X | |||
| Price To Sales | 34.76 X | |||
| Revenue | 118.3 M | |||
| EBITDA | (1.41 B) | |||
| Cash And Equivalents | 747.47 M | |||
| Cash Per Share | 15.30 X | |||
| Debt To Equity | 1.20 % | |||
| Book Value Per Share | 4.21 X | |||
| Cash Flow From Operations | (1.52 B) | |||
| Earnings Per Share | (16.78) X | |||
| Total Asset | 439.38 M | |||
About Oncopeptides Performance
Assessing Oncopeptides' fundamental ratios provides investors with valuable insights into Oncopeptides' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Oncopeptides is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden.Things to note about Oncopeptides AB performance evaluation
Checking the ongoing alerts about Oncopeptides for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncopeptides AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncopeptides AB generated a negative expected return over the last 90 days | |
| Oncopeptides AB may become a speculative penny stock | |
| Oncopeptides AB has high historical volatility and very poor performance | |
| Oncopeptides AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 118.3 M. Net Loss for the year was (1.43 B) with profit before overhead, payroll, taxes, and interest of 74.16 M. | |
| Oncopeptides AB has accumulated about 747.47 M in cash with (1.52 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Oncopeptides' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncopeptides' stock is overvalued or undervalued compared to its peers.
- Examining Oncopeptides' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncopeptides' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncopeptides' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncopeptides' stock. These opinions can provide insight into Oncopeptides' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.